See today's BioWorld Asia
To read the full story, subscribe or sign in.

Divestiture unrest as Viatris sheds biosimilars in $3.34B

March 1, 2022
By Randy Osborne
Biocon Ltd. said its subsidiary Biocon Biologics Ltd. has agreed to buy out partner Viatris Inc., bringing aboard the latter’s biosimilars business, for $3.34 billion.
BioWorld Asia Deals and M&A Biosimilar Asia-Pacific